Business
SenesTech Announces 2021 Third Quarter Financial and Operational Results
Revenue More Than Doubles from the Third Quarter in 2020 and up 14% Sequentially PHOENIX, Nov. 10, 2021 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES,
About this update from Senestech, Inc.
[{"type":"text","content":"Revenue More Than Doubles from the Third Quarter in 2020 and up 14% Sequentially\n\n\nPHOENIX, Nov. 10, 2021 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, \"SenesTech\" or the \"Company\"), (www.senestech.com) the rodent fertility control experts and inventors of the first and only EPA registered rat contraceptive, ContraPest®, announced today revenues for the third quarter of 2021 more than doubled compared to the same period a year ago, and are up 14% sequentially. Year-to-date nine-month revenues were also more than double the same period last year. The record quarterly and year-to-date results are being driven by growth in each of the Company's targeted market verticals of agribusiness, municipalities, zoos and sanctuaries, commercial applications, and direct to consumer. \n\n \n \n \n \n \n \n\n \nThe Company has recently deployed key sales acceleration tactics to drive increased awareness and recognition of ContraPest, including enhanced marketing techniques; new advertising and public relations initiatives through its \"Operation Rat Race\" campaign; development of a new website and branding; the launch of an ecommerce site, ContraPestStore.com; completion of compelling real world long-term studies across key market segments; and enhanced strategic partnerships and collaborations with key distributors and pest management professionals.\nThese strategies, against the backdrop of favorable legislative changes and growing environmental awareness, are all contributing to the record quarterly results. The Company is now supporting approximately 1,200 active customers, with more than 350 new and reactivated customers added during the third quarter. Driven by California's legislation restricting the use of major second-generation anticoagulant rodenticides (SGAR), year-to-date sales to California are nearly 30% of overall sales. \n\"I am pleased to be reporting yet another quarter with record quarterly revenues as increased adoption of the powerful, effective, and sustainable tool to control rat infestations, ContraPest, continues to accelerate,\" said Ken Siegel, SenesTech's Chief Executive Officer. \"Our enhanced sales and marketing initiatives, including the launch of Operation Rat Race in September, are continuing to build awareness and recognition of the unique and compelling benefits of ContraPest, especially when used as...